Copyright Reports & Markets. All rights reserved.

Global Cancer Tumor Profiling Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Cancer Tumor Profiling Industry
  • 1.7 COVID-19 Impact: Cancer Tumor Profiling Market Trends

    • 2 Global Cancer Tumor Profiling Quarterly Market Size Analysis

    • 2.1 Cancer Tumor Profiling Business Impact Assessment - COVID-19
      • 2.1.1 Global Cancer Tumor Profiling Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Cancer Tumor Profiling Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Cancer Tumor Profiling Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Cancer Tumor Profiling Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Cancer Tumor Profiling Market
    • 3.4 Key Players Cancer Tumor Profiling Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Cancer Tumor Profiling Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Next-generation Sequencing (NGS)
      • 1.4.2 Polymerase Chain Reaction (PCR)
      • 1.4.3 Immunohistochemistry (IHC)
      • 1.4.4 In Situ Hybridization (ISH)
      • 1.4.5 Microarray
      • 1.4.6 Others
    • 4.2 By Type, Global Cancer Tumor Profiling Market Size, 2019-2021

    5 Impact of Covid-19 on Cancer Tumor Profiling Segments, By Application

    • 5.1 Overview
      • 5.5.1 Personalized Medicine
      • 5.5.2 Diagnostics
      • 5.5.3 Biomarker Discovery
      • 5.5.4 Prognostics
      • 5.5.5 Research Applications
    • 5.2 By Application, Global Cancer Tumor Profiling Market Size, 2019-2021
      • 5.2.1 By Application, Global Cancer Tumor Profiling Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Qiagen N.V.
      • 7.1.1 Qiagen N.V. Business Overview
      • 7.1.2 Qiagen N.V. Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.1.3 Qiagen N.V. Cancer Tumor Profiling Product Introduction
      • 7.1.4 Qiagen N.V. Response to COVID-19 and Related Developments
    • 7.2 Roche Molecular Systems Inc.
      • 7.2.1 Roche Molecular Systems Inc. Business Overview
      • 7.2.2 Roche Molecular Systems Inc. Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.2.3 Roche Molecular Systems Inc. Cancer Tumor Profiling Product Introduction
      • 7.2.4 Roche Molecular Systems Inc. Response to COVID-19 and Related Developments
    • 7.3 Abott Molecular
      • 7.3.1 Abott Molecular Business Overview
      • 7.3.2 Abott Molecular Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.3.3 Abott Molecular Cancer Tumor Profiling Product Introduction
      • 7.3.4 Abott Molecular Response to COVID-19 and Related Developments
    • 7.4 Illumina Inc.
      • 7.4.1 Illumina Inc. Business Overview
      • 7.4.2 Illumina Inc. Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.4.3 Illumina Inc. Cancer Tumor Profiling Product Introduction
      • 7.4.4 Illumina Inc. Response to COVID-19 and Related Developments
    • 7.5 NeoGenomics Laboratories
      • 7.5.1 NeoGenomics Laboratories Business Overview
      • 7.5.2 NeoGenomics Laboratories Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.5.3 NeoGenomics Laboratories Cancer Tumor Profiling Product Introduction
      • 7.5.4 NeoGenomics Laboratories Response to COVID-19 and Related Developments
    • 7.6 HTG Molecular Diagnostic
      • 7.6.1 HTG Molecular Diagnostic Business Overview
      • 7.6.2 HTG Molecular Diagnostic Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.6.3 HTG Molecular Diagnostic Cancer Tumor Profiling Product Introduction
      • 7.6.4 HTG Molecular Diagnostic Response to COVID-19 and Related Developments
    • 7.7 Genomic Health Inc.
      • 7.7.1 Genomic Health Inc. Business Overview
      • 7.7.2 Genomic Health Inc. Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.7.3 Genomic Health Inc. Cancer Tumor Profiling Product Introduction
      • 7.7.4 Genomic Health Inc. Response to COVID-19 and Related Developments
    • 7.8 Hologic Gen-Probe
      • 7.8.1 Hologic Gen-Probe Business Overview
      • 7.8.2 Hologic Gen-Probe Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.8.3 Hologic Gen-Probe Cancer Tumor Profiling Product Introduction
      • 7.8.4 Hologic Gen-Probe Response to COVID-19 and Related Developments
    • 7.9 BD Biosciences
      • 7.9.1 BD Biosciences Business Overview
      • 7.9.2 BD Biosciences Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.9.3 BD Biosciences Cancer Tumor Profiling Product Introduction
      • 7.9.4 BD Biosciences Response to COVID-19 and Related Developments
    • 7.10 Siemens Healthineers
      • 7.10.1 Siemens Healthineers Business Overview
      • 7.10.2 Siemens Healthineers Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.10.3 Siemens Healthineers Cancer Tumor Profiling Product Introduction
      • 7.10.4 Siemens Healthineers Response to COVID-19 and Related Developments
    • 7.11 Claris Life Sciences
      • 7.11.1 Claris Life Sciences Business Overview
      • 7.11.2 Claris Life Sciences Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.11.3 Claris Life Sciences Cancer Tumor Profiling Product Introduction
      • 7.11.4 Claris Life Sciences Response to COVID-19 and Related Developments
    • 7.12 Personal Genome Diagnostics, Inc.
      • 7.12.1 Personal Genome Diagnostics, Inc. Business Overview
      • 7.12.2 Personal Genome Diagnostics, Inc. Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.12.3 Personal Genome Diagnostics, Inc. Cancer Tumor Profiling Product Introduction
      • 7.12.4 Personal Genome Diagnostics, Inc. Response to COVID-19 and Related Developments
    • 7.13 Perthera, Inc.
      • 7.13.1 Perthera, Inc. Business Overview
      • 7.13.2 Perthera, Inc. Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.13.3 Perthera, Inc. Cancer Tumor Profiling Product Introduction
      • 7.13.4 Perthera, Inc. Response to COVID-19 and Related Developments
    • 7.14 Foundation Medicine, Inc
      • 7.14.1 Foundation Medicine, Inc Business Overview
      • 7.14.2 Foundation Medicine, Inc Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.14.3 Foundation Medicine, Inc Cancer Tumor Profiling Product Introduction
      • 7.14.4 Foundation Medicine, Inc Response to COVID-19 and Related Developments
    • 7.15 V., Strand
      • 7.15.1 V., Strand Business Overview
      • 7.15.2 V., Strand Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.15.3 V., Strand Cancer Tumor Profiling Product Introduction
      • 7.15.4 V., Strand Response to COVID-19 and Related Developments
    • 7.16 ApoCell
      • 7.16.1 ApoCell Business Overview
      • 7.16.2 ApoCell Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.16.3 ApoCell Cancer Tumor Profiling Product Introduction
      • 7.16.4 ApoCell Response to COVID-19 and Related Developments
    • 7.17 Contextual Genomics
      • 7.17.1 Contextual Genomics Business Overview
      • 7.17.2 Contextual Genomics Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.17.3 Contextual Genomics Cancer Tumor Profiling Product Introduction
      • 7.17.4 Contextual Genomics Response to COVID-19 and Related Developments
    • 7.18 Agendia
      • 7.18.1 Agendia Business Overview
      • 7.18.2 Agendia Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.18.3 Agendia Cancer Tumor Profiling Product Introduction
      • 7.18.4 Agendia Response to COVID-19 and Related Developments
    • 7.19 GenScript
      • 7.19.1 GenScript Business Overview
      • 7.19.2 GenScript Cancer Tumor Profiling Quarterly Revenue, 2020
      • 7.19.3 GenScript Cancer Tumor Profiling Product Introduction
      • 7.19.4 GenScript Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Cancer Tumor Profiling, including the following market information:
      Global Cancer Tumor Profiling Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Cancer Tumor Profiling Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Cancer Tumor Profiling Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Cancer Tumor Profiling Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Qiagen N.V., Roche Molecular Systems Inc., Abott Molecular, Illumina Inc., NeoGenomics Laboratories, HTG Molecular Diagnostic, Genomic Health Inc., Hologic Gen-Probe, BD Biosciences, Siemens Healthineers, Claris Life Sciences, Personal Genome Diagnostics, Inc., Perthera, Inc., Foundation Medicine, Inc, V., Strand, ApoCell, Contextual Genomics, Agendia, GenScript, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Next-generation Sequencing (NGS)
      Polymerase Chain Reaction (PCR)
      Immunohistochemistry (IHC)
      In Situ Hybridization (ISH)
      Microarray
      Others

      Based on the Application:
      Personalized Medicine
      Diagnostics
      Biomarker Discovery
      Prognostics
      Research Applications

      Buy now